Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes

Diabetes

Volumn 50, Issue 5, 2001, Pages 1166-1170

  Emoto, Masahiro ^a   Anno, Takatoshi ^a   Sato, Yutaka ^a   Tanabe, Katsuya ^a   Okuya, Shigeru ^a   Tanizawa, Yukio ^a   Matsutani, Akira ^a   Oka, Yoshitomo ^a,b  

^a YAMAGUCHI UNIVERSITY   (Japan)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MESSENGER RNA; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE; VASCULOTROPIN;

ADIPOCYTE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET THERAPY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX RATIO;

EID: 0035029848     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.5.1166     Document Type: Article

References (41)

1. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM
2. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
3. Troglitazone and Exogenous Insulin Study Group: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
4. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
5. Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene
6. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ)
7. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
8. Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy
9. From the Food and Drug Administration
10. Hepatic dysfunction associated with troglitazone
11. Diabetes drug withdrawn after reports of hepatic events
12. Activators of the nuclear receptor PPAR γ enhance colon polyp formation
13. Activation of the peroxisome proliferator-activated receptor promotes the development of colon tumors in C57BL/6J-APCMin/+ mice
14. Differentiation and reversal of malignant changes in colon cancer through PPAR γ
15. Vascular endothelial growth factor is a secreted angiogenic mitogen
16. Vascular permeability factor, an endothelial cell mitogen related to PDGF
17. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
18. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
19. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
20. Partial purification and characterization of a vascular permeability factor secreted by a human colon adenocarcinoma cell line
21. Vascular endotlielial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
22. Vascular endothelial growth factor in diabetic retinopathy
23. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
24. Vascular endothelial growth factor and diabetes: The agonist versus antagonist paradox
25. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart
26. Ischaemia-induced expression of bFGF in normal skeletal muscle: A potential paracrine mechanism for mediating angiogenesis in ischaemic skeletal muscle
27. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase. DNA synthesis, and glucose transporter translocation
28. Overexpression of catalytic subunit p110 α of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes
29. Analysis of RNA by Northern and slot hybridization
30. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer
31. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model
32. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate
33. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome
34. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome
35. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia
36. Vascular endothelial growth factor: Regulation by cell differentiation and activated second messenger pathways
37. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
38. The mouse gene for vascular endothelial growth factor: Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences
39. The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR γ and CBP
40. Role of CBP/P300 in nuclear receptor signalling
41. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors